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ABSTRACT
Introduction Sarcomas are rare tumours with 
considerable heterogeneity. Early and accurate diagnosis 
is important to optimise patient outcomes in terms of 
local disease control, overall survival (OS) and health- 
related quality of life (HRQoL). Time to diagnosis is 
variable in bone as well as soft tissue sarcoma. Possible 
factors for a long time from first symptom to diagnosis 
(the total interval) include patient, tumour and healthcare 
characteristics, but until now the most relevant risk 
factors and its association with outcomes remain 
unknown. Our study aims to (1) quantify total interval, 
the time interval from first symptom until (histological) 
diagnosis; (2) identify factors associated with interval 
length and (3) determine the association between total 
interval and HRQoL, stage and tumour size at diagnosis, 
progression- free survival (PFS) and OS.
Methods and analysis We will conduct a longitudinal, 
prospective, international, multicentre cohort study 
among patients aged ≥18 years with newly diagnosed 
bone or soft tissue sarcoma at eight centres (three in 
UK, five in The Netherlands). Patients will be asked to 
complete questionnaires at five points in time; one at 
diagnosis and at follow- up points of 3, 6, 12 and 24 
months. Questionnaire data is collected within the Patient 
Reported Outcomes Following Initial treatment and Long 
term Evaluation of Survivorship (PROFILES) registry: an 
international data management system for collection of 
patient- reported outcomes. Clinical data will be extracted 
from patient records. The primary endpoint is HRQoL at 
diagnosis, measured with the EORTC QLQ- C30. Secondary 
endpoints are stage and tumour size at diagnosis, PFS, 
OS, additional patient- reported outcomes, such as quality- 
adjusted life years and psychological distress.
Ethics and dissemination Ethical approval was given 
by the Health Research Authority and Research Ethics 
Committee for the United Kingdom (18/WA/0096) and 
medical ethical committee of Radboudumc for The 
Netherlands (2017-3881). Results will be presented in 
peer- reviewed journals and presented at meetings.
Trial registration number NCT03441906.
INTRODUCTION
Sarcomas are a group of solid mesenchymal 
tumours, which comprise more than 70 histo-
logical subtypes, with considerable hetero-
geneity with respect to age at diagnosis, 
location, biological behaviour and outcome.1 
Approximately 80% of sarcomas are soft tissue 
sarcomas (STS), the remainder are bone 
sarcomas. Sarcomas are typical examples 
of so- called rare cancers, with an estimated 
European incidence of 4–5 per 100 000 per 
year when taken all together,2 accounting for 
1% of adult solid malignant cancers.3 Patients 
with rare cancers have a higher mortality rate 
than those with common cancers, due to 
delays in diagnosis, suboptimal or inadequate 
treatment, fewer developments in novel ther-
apies and opportunities to participate in clin-
ical trials.4
Early and accurate diagnosis of cancer 
is important to optimise patient outcomes 
in terms of local disease control, overall 
survival (OS) and health- related quality of 
life (HRQoL).5 6 However, because of the 
heterogeneity and rarity of sarcomas, there is 
a lack of public awareness, limited experience 
Strengths and limitations of this study
 ► The international design allows for comparison of 
healthcare systems and its influence on total inter-
val length.
 ► Multicentre, prospective design allows reliable com-
parison of sarcoma subgroups to make clinically 
relevant recommendations to improve total interval.
 ► Inclusion of patients at diagnosis minimises recall 
bias for total interval length.
 ► Patients were actively involved in the design of this 
study and mentioned earlier diagnosis and patient- 
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of primary and secondary healthcare professionals and 
absence of a typical presentation, resulting in late refer-
rals to specialist sarcoma centres and prolonged time to 
diagnosis.7
Time to diagnosis can be defined according to the 
research framework from Olesen et al,8 which we adapted 
to the situation as applicable for sarcomas.9 10 The time 
between first symptom and (histological) diagnosis is 
known as the total interval. This includes a patient and 
diagnostic interval, defined as time between onset of 
symptoms until consultation of a healthcare profes-
sional and time between consultation of a healthcare 
professional and diagnosis, respectively. The latter can 
be further divided into a primary, secondary and tertiary 
care interval, each of which refers to first consultation 
until referral to the next caregiver or diagnosis.
Possible risk factors for a prolonged total interval 
could be patient, tumour or healthcare system charac-
teristics. In order to study the latter, it is informative to 
compare patients from different countries. In both the 
Netherlands and UK, general practitioners (GPs) have 
an important role as healthcare gatekeepers. In general, 
people consult their GP who then decides whether 
referral is warranted and determines the acuteness and 
location of the referral. In the UK, privately insured 
patients can also self- refer to a hospital without seeing a 
GP. Furthermore, within the UK, a considerable amount 
of patients with cancer is diagnosed at an emergency 
department, associated with worse outcomes.11 Sarcoma 
care is formally centralised within the UK, whereas the 
Netherlands has bone sarcoma centres, and referral to 
dedicated STS centres is encouraged, but not commis-
sioned. Furthermore, cultural differences may play a role 
in patient behaviour. Also, longer travel time to a sarcoma 
centre in the UK compared with the Netherlands may 
also affect total interval length.
Up to now, only few studies regarding total interval 
length and clinical outcomes in sarcoma have been 
published, most were retrospective and included mainly 
children. Some studies found that a longer total interval 
worsened OS, while others did not find inferior clin-
ical outcomes.10 Researchers have argued that this lack 
of an association, often referred to as the ‘waiting- time 
paradox’, may be because the studies have not been able 
to adequately adjust for the aggressiveness of the cancer 
tumours. The most significant effect of a long interval for 
sarcomas seems to be the increasing size of the lesion,12 
with consequent decreased chance of uncomplicated 
resection with clear surgical margins, a greater risk of 
amputation and increased risk of developing metas-
tases.13 This may also affect patient- reported outcomes 
such as HRQoL of patients with sarcoma.
HRQoL is the patients’ perception of his overall health 
in relation to physical, psychological and social aspects 
in life.14 Three systematic reviews have been published 
on HRQoL of patients with sarcoma, however, none of 
these looked at the association of total interval length 
and HRQoL.15–17 In other cancers and chronic diseases, 
lengthening of total interval was associated with decreased 
HRQoL.18 19 HRQoL is an interesting outcome parameter 
for evaluating consequences of long total interval length 
and provides an insight into the patient’s experience of 
the consequences of diagnostic delay. In addition to using 
patient- reported outcomes as a measure for quality of 
care, HRQoL can be used to conduct cost- utility analysis 
to estimate the ratio between the cost of a prolonged total 
interval and the benefit of earlier diagnosis in terms of 
life- years (quality- adjusted life years (QALY)).
Until now, risk factors for a long total interval in adult 
sarcoma care as well as its effect on clinical and patient- 
reported outcomes remain unknown. These need to be 
studied in well- designed, large, prospective studies in 
order to prioritise interventions to optimise the total 
interval. Our study aims to quantify total interval, iden-
tify independent variables associated with a long interval 
(such as demographic and clinical factors) and deter-
mine the association between total interval and other 
dependent variables, such as HRQoL, stage and tumour 
size at diagnosis, progression- free survival (PFS) and OS 
(figure 1).
METHODS AND ANALYSIS
Study design and setting
We will conduct a longitudinal, prospective, cohort study 
among adult sarcoma patients, newly diagnosed in one of 
the participating study centres (five centres in the Neth-
erlands: Radboud University Medical Centre Nijmegen, 
Erasmus Medical Centre Rotterdam, University Medical 
Centre Leiden, University Medical Centre Groningen, 
Netherlands Cancer Institute Amsterdam; three centres in 
the UK: The Royal Marsden London, Christie Manchester, 
Royal Orthopaedic Hospital Birmingham, all NHS Foun-
dation Trusts). The study started recruitment at the first 
centre in the Netherlands in February 2018 and in the 
UK in October 2018 and is currently recruiting.
After informed consent, patients are being asked 
to complete questionnaires at five points in time: the 
first at baseline, preferably before start of treatment or 
within 4 weeks thereafter, and at 3, 6, 12 and 24 months 
follow- up (table 1). Baseline questionnaire completion 
will take about 45 min, follow- up questionnaires will take 
20–30 min each.
Patient and public involvement
The different patient- reported outcome measures were 
selected in consultation with patient advocates. The 
Sarcoma Patients EuroNet, an international network of 
patient advocacy groups, has formulated research prior-
ities, at least two of which will be addressed by our study: 
(1) earlier diagnosis and (2) patient- reported outcomes 
such as HRQoL.20 The questionnaire was pilot tested 
by patients, for acceptability and understandability. 
Study documents were reviewed by the patients who are 
members of the Royal Marsden Hospital Patient and 
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of Radboudumc. The panel and committee provided 
feedback on the protocol, questionnaires, patient infor-
mation sheet and informed consent form, regarding 
content and readability, and changes were incorpo-
rated in the final documents. Patients have been and 
will be involved in study- related presentations and 
publications.
Participants
Eligible patients are invited by their treating physician 
or a member of the research team. Inclusion criteria 
are: (1) aged ≥18 years; (2) new histological diagnosis 
of sarcoma as confirmed by a sarcoma histopathologist 
(according to the International Statistical Classification 
 
Dependent variables (outcomes) 
Health-related quality of life – QALYs 
Psychological distress 








Route to diagnosis  
Patient interval Diagnostic interval 
Primary care interval 
Secondary care interval 
Tertiary care interval 
Independent variables 
Demographic factors 
-Age and gender 





-Symptoms before diagnosis  












-Access to care 
-Referral patterns 
-Number of prediagnosis consultations 
 
Figure 1: schematic representation of study objectives 
Figure 1 Conceptual model.
Table 1 Time points and questionnaire items
Item (number of items) Scale 0 months 3 months 6 months 12 months 24 months
Characteristics
  Sociodemographic (max 20) X X X X X
  Comorbidity (15) SCQ X X X
  Total interval (max 42) Own design X X X X X
  Health literacy (1) SBSQ X
  Social support (1) QLCS X X X
  Self- efficacy (10) GSE X
  Coping (28) Brief COPE X
  Resilience (6) BRS X
Outcomes
  Health- related quality of life (30) EORTC QLQ- C30 version 3.0 X X X X X
  Quality- adjusted life years (6) EQ5D5L X X X X X
  Psychological distress (14) HADS X X X X X
  Financial impact (20) Own design X X X X X
  Information provision (max 26) Profiles registry X
  Quality of care (max 23) PSQ-18 and 3–5 single items X X X X X
  Total number of items 194 158 105 113 114
BRS, brief resilience scale; COPE, Coping Orientation to Problems Experienced; EORTC QLQ, European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire; EQ5D5L, European Quality of life 5 Dimensions 5 Levels; GSE, general self- efficacy; HADS, 
hospital anxiety and depression scale; PSQ, patient satisfaction questionnaire; QLCS, quality of life- cancer survivors; SBSQ, set of brief 
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Of Diseases And Related Health Problems, 10th revi-
sion, German Modification (ICD-10- GM) codes C40 and 
C41 for bone sarcoma and C49 for soft- tissue sarcoma); 
(3) able to communicate in English or Dutch and to 
complete questionnaires themselves; (4) mental capacity 
to provide informed consent and participate in the study 
(as determined by the healthcare professional) and (5) 
diagnosed at or referred to one of the participating hospi-
tals. Exclusion criteria are: (1) too ill to complete ques-
tionnaires (according to treating physician—patients 
who experience symptoms are still eligible); (2) desmoid 
fibromatosis and gastrointestinal stromal tumours due to 
the different nature of the diseases (ICD-10- GM codes 
C15-20, C26, C48 and C80).
Data collection
Eligible patients receive a patient information sheet, 
which explains the goals and procedure of the study. It 
includes a link to a secure website ( www. profielstudie. nl 
for both English and Dutch patients), a login name and a 
password. After logging in, patients can provide informed 
consent and complete questionnaires online. Patients 
without access to internet or preference of written commu-
nication receive a paper version of the informed consent 
form and questionnaire. Questionnaires completed 
on paper will be entered via the data entry option into 
the Patient Reported Outcomes Following Initial treat-
ment and Long term Evaluation of Survivorship system 
(PROFILES; www. profilesregistry. nl21) by a member 
of the study team. The data entry portal has the same 
format as the online questionnaire data, minimising the 
chance of errors and enhancing data extraction. Paper 
questionnaires will be stored in a secured room at study 
coordinating sites (Radboudumc and Royal Marsden 
Hospital). PROFILES is a data management system set up 
in 2009 in the Netherlands for the study of physical and 
psychosocial impact of cancer and its treatment. The data 
collected in PROFILES is stored on a secure server in the 
Netherlands. In order to retrieve the data, an authorised 
member of the study team can login and download an 
SPSS or Excel file containing the encoded questionnaire 
data. PROFILES has been developed to the requirements 
of the higher education and research community and 
allows end- to- end encryption.
The research coordinator has access to a password- 
protected file that links patients’ study numbers to their 
electronical patient record number. Clinical data and 
survival data will be retrieved from the patients’ medical 
record by a member of the study team into the electronic 
case report forms (eCRF) database (MACRO), which 
is maintained according to current norms and Interna-
tional Council for Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human 
Use - Good Clinical Practice (ICH- GCP)) standards and 
is password protected. Patient records will not leave the 
hospital.
Finally, questionnaire data will be linked with the eCRF 
database (all encoded data) using study numbers. The 
combined dataset will be stored under appropriate pass-
word protection. Data will be recorded and retained in 
accordance with the Data Protection Act 1998.
Case report forms
CRFs will be completed at five time points during the 
study. The first will be completed on inclusion, the 
following time points coincide with the completion of 
follow- up questionnaires. The last CRF is also the end- of- 
study CRF, which can be completed before 24 months if a 
patient withdraws or deceases. The information collected 
on the CRF will be stored on a secure CRF database using 
anonymous study numbers. Data collected includes docu-
mentation of eligibility criteria, date of diagnosis, tumour 
characteristics such as histology, tumour, node and metas-
tasis (TNM) stage, tumour size, treatment regiment, 
re- occurrence of disease or metastases, reason for with-
drawal of the study and time of death, if applicable.
Questionnaires
We have combined self- designed questions and several 
validated questionnaires designed by other researchers 
(details below). For non- commercial scientific use, no 
formal licenses are needed for the use of these question-
naires. Self- designed items and existent questionnaires 
not available in both English and Dutch were translated 
with formal forward- backward translation by bilingual 
speakers. Table 1 summarises the time points at which 
each construct is being measured.
Sociodemographics
The questionnaires contain questions on sociodemo-
graphic characteristics of the participant at the time of 
questionnaire completion, such as marital status and 
educational level. Comorbidity is being measured with 
the Self- administered Comorbidity Questionnaire (SCQ), 
which is a validated list where patients report their comor-
bidity during the past year.22
Total interval
A 42- item list was self- designed to assess the total interval. 
Examples of questions are as follows: ‘With which symp-
tom(s), caused by the sarcoma, did you first go to a 
doctor?’, ‘To which doctor did you first talk about your 
symptoms?’ and ‘How often did you talk to the following 
doctors about your symptoms belonging to sarcoma, 
before you heard you had a sarcoma?’ At follow- up, a few 
questions are repeated to complete data collection. We 
will sample survey the reported dates by cross- checking 
them with the patient’s record. If more than 5% of the 
cross- checked dates deviates more than 1 month from the 
registered dates in the medical record, we will cross- check 
all dates and use the clinical reported dates for statistical 
analysis.
Health literacy is being assessed by a Dutch adaptation 
of Chew’s Set of Brief Screening Questions (SBSQ) in a 
single- item question.23–25
Social support is being assessed by one single item: 
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sufficient?’ extracted from the Quality of Life- Cancer 
Survivors questionnaire.26 27
Self- efficacy is measured with the General Self- Efficacy 
scale (GSE).28 This 10- item scale assesses a general sense 
of perceived self- efficacy with the aim to predict coping 
with daily hassles as well as adaptation after experiencing 
a stressful life event. Self- efficacy is the belief that one can 
perform a novel or difficult task, or cope with adversity. 
Perceived self- efficacy facilitates goal- setting, effort invest-
ment, persistence in face of barriers and recovery from 
setbacks. Responses are made on a 4- point scale. A higher 
final composite score correlates with higher perceived 
self- efficacy.
Coping is assessed in the 3- month questionnaire with 
the help of the brief Coping Orientation to Problems 
Experienced (COPE).29 Coping is about emotional and 
mental reactions, which enable people to activate sources 
of help needed to cope with stress and problems. This 
28- item scale measures 14 positive and negative styles of 
coping on a 5- point Likert- scale.
Resilience is measured in the 6- month questionnaire 
using the Brief Resilience Scale (BRS).30 Resilience is a 
skill that helps people recover from a life event. People 
with high (perceived) resilience can move on faster after 
a setback. The BRS is a 6- item scale with a 5- point Likert 
scale.
Health-related quality of life
HRQoL is being assessed with the EORTC QLQ- C30, 
V.3.0, which is validated and available in English and 
Dutch.31 This 30- item HRQoL questionnaire consists of 
five functional scales (physical, role, cognitive, emotional 
and social), a global quality of life scale, three symptom 
scales (fatigue, pain, nausea and vomiting) and a number 
of single items assessing common symptoms (dyspnoea, 
loss of appetite, sleep disturbance, constipation and diar-
rhoea) and perceived financial impact of the disease. 
After linear transformation, all scales and single- item 
measures have scores ranging from 0 to 100. A higher 
score on the functional scales and global QoL means 
better functioning and HRQoL, whereas a higher score 
on the symptom scales means more complaints.
Quality-adjusted life years
QALY is being measured with the EuroQol EQ- 5D- 5L, 
which is a descriptive system for the measurement 
of health.32 It measures HRQoL on five dimensions: 
mobility, self- care, usual activities, pain- discomfort and 
anxiety- depression. To make the EQ- 5D- 5L suitable for 
use in economic evaluations, the health status needs to 
be valued with a preference- elicitation method.33 Both 
Dutch and English national values were collected and 
subsequently modelled.34 35
Psychological distress
Psychological distress is being assessed with the Hospital 
Anxiety and Depression Scale (HADS), which is vali-
dated in Dutch and English.36 This 14- item instrument 
measures psychological distress, with seven items each 
assessing anxiety and depression. The summed total score 
of the HADS will be used to reflect psychological distress. 
Higher total scores are indicative of more psychological 
distress.
Financial impact
We self- designed a 20- item questionnaire regarding finan-
cial barriers to care. The questions were designed based 
on a literature study of items that are important in health- 
seeking behaviour but have not been validated. Topics 
covered are financial barriers to care, financial impact of 
living with cancer, personal expenses and potential solu-
tions for reducing financial impacts.
Information provision
Five self- designed questions with multiple items are being 
asked to identify time points and subjects on which partic-
ipants would like more information.
Quality of care
Quality of care is being assessed with the 18- item Patient 
Satisfaction Questionnaire (PSQ-18),37 available in both 
English and Dutch.38 39 This instrument yields scores for 
each of the seven different subscales: general satisfaction, 
technical quality, interpersonal manner, communica-
tion, financial aspects, time spent with doctor and acces-
sibility and convenience. High scores reflect satisfaction 
with medical care. In addition, three to five self- designed 
single items to assess overall satisfaction of care at the 
primary doctor’s office, hospital and sarcoma centre are 
being asked.
Endpoints
The primary endpoint is HRQoL of patients with sarcoma 
at diagnosis (baseline) as measured with the EORTC 
QLQ- C30 (global health status). Secondary endpoints 
are: QALY, psychological distress, stage and tumour size 
at diagnosis, PFS and OS.
If subgroups are large enough, we will conduct these 
analyses for different clinically relevant subgroups, such 
as different histological subtypes, geographical areas, and 
so on.
Sample size calculation
We expect a minimum response rate at baseline of 65%, 
based on rates in other PROFILES studies.40 During 
follow- up, after completion of the first questionnaire, we 
expect a response rate of 80%. The definition of a long 
total interval will follow from our statistical analysis (see 
below), however, if the analysis does not provide a clear 
cut- off point, we will use the last quartile to define the 
population with a long total interval.
Using the EORTC QLQ- C30, differences of at least 10 
points have been considered as clinically meaningful.41 
Based on results from our ongoing PROFILES studies, 
an SD of about 20 points for each scale can be expected. 
Using an alpha of 0.05, a power of 0.90 and a long diag-
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sarcoma, with the expected drop- out, would require 265 
patients.42 In order to make country- to- country compari-
sons, we aim to include 265 Dutch and 265 English patients 
in a time frame of 18 months with a total follow- up of 24 
months.
Statistical analysis
Descriptive statistics (means, SD, median, range, frequen-
cies) will be used to quantify diagnostic intervals and 
describe the study population.
HRQoL at baseline will be calculated according to the 
EORTC scoring manual.43 Missing items will be imputed 
according to these guidelines, after which an available 
case analysis will be performed.
The relationship between total interval length and 
HRQoL at baseline will be investigated by plotting 
HRQoL against total interval length as a continuous vari-
able. Linear regression will be used to assess their associ-
ation. The time point providing a significant difference 
in HRQoL will be used as a cut- off point for further anal-
ysis. If this does not provide a clear cut- off point, logistic 
regression will be used to assess an association between 
baseline HRQoL and total interval grouped into suitable 
categories, such as quartiles. The last quartile will then be 
used to define the population with a long interval.
Apart from statistical significance, we will look at clini-
cally relevant differences in HRQoL scores as determined 
by Cocks et al.42 A small effect size will then be considered 
as an appropriate value for a cut- off point.
A series of univariate logistic regression analyses will 
be conducted to assess the relationship between total 
interval length (grouped by the cut- off point as defined 
by the previous analysis) and independent variables, such 
as patient, tumour and healthcare system risk factors. All 
factors with p<0.1 will then be used in multiple logistic 
regression analysis (forced entry method) to investigate 
whether these factors are independently associated with 
total interval length.
Apart from total interval length, the association of 
other patient and tumour characteristics (such as self- 
efficacy, social support, financial difficulties, histology), 
and HRQoL at baseline will be investigated using univar-
iate logistic regression analysis. Using the forced entry 
method, multiple logistic regression analysis will then be 
performed with all factors with p<0.1 to assess what factors 
are independently associated with baseline HRQoL.
Change in HRQoL during the follow- up period of 
2 years and factors associated with changes in HRQoL 
will be analysed using repeated measures mixed models. 
This will be compared between patients with a short and 
long total interval, using repeated measures analysis of 
variance, controlling for relevant patient and tumour 
characteristics, and the patient’s baseline score. Clini-
cally relevant differences will be assessed using Cocks’ 
method.41 42
Other patient- reported outcomes such as QALYs and 
psychological distress will be analysed in the same way.
Multivariate analyses will be performed to examine 
associations between total interval length and (1) QALYs, 
(2) psychological distress, (3) stage at diagnosis and (4) 
tumour size. These analyses will be corrected for poten-
tial confounders including patient and tumour character-
istics and healthcare system.
Both unadjusted and adjusted multivariate Cox propor-
tional hazard regression analyses will be used to examine 
whether a long total interval is associated with PFS or OS.
PFS is defined as the time interval between diagnosis 
until clinical or radiological progression, as assessed by 
the treating consultant. OS is defined as the time from 
diagnosis until death.
Statistical analyses will be performed using IBM SPSS 
V.25.0; two- sided p values <0.05 will be considered statis-
tically significant.
Missing data
Online questionnaire completion does not allow for 
missing data, unless participants have not completed the 
entire questionnaire, as patients are unable to proceed to 
the next question until all questions on the current page 
have been answered. Items missing from paper question-
naires will be dealt with as missing at random. The EORTC 
QLQ- C30 allows imputation of missing values according 
to the EORTC scoring manual guideline.43 Numbers of 
missing items will be reported.
Impact of COVID-19 pandemic on QUEST
A national lockdown was introduced across The Neth-
erlands on 16 March and the UK on 23 March 2020, 
as part of the national strategies to flatten the curve of 
the COVID-19 pandemic. On 23 March, recruitment 
for QUEST was finished in The Netherlands, while the 
recruitment target was almost reached in the UK. The 
COVID-19 pandemic forced us to put the recruitment 
on hold in the UK. The negative consequences of the 
pandemic on cancer diagnostic timelines (prolonged), 
incidence (reduced) and eventually cancer outcomes 
have been shown and modelled by several studies.44–46 We 
will therefore discuss the necessity to reopen recruitment 
in the UK with our statistical department, as patients 
recruited during the pandemic will not be representative 
for the sarcoma population outside COVID-19 times and 
will bias our results.
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